Appendix Table C123. Study withdrawals and adverse events (outcomes part D), glycemic control trials

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Study Withdrawals: Any, n/N (%)** | **Serious Adverse Events: Any****n/N (%)** | **Study Withdrawals Due to Serious Adverse Events: Any, n/N (%)** | **Adverse Event: Any****n/N (%)** | **Adverse Event: Specific, n/N (%)** | **Renal Adverse Event: Any, n/N (%)** |
| **IT** | **CT** |  |  | **IT** | **CT** | **IT** | **CT** | **IT** | **CT** | **IT** | **CT** |
| Duckworth, 200985 |  |  |  |  |  |  |  |  | Severe hypoglycemia: 5/36 (13.9); DKA: 3/36 (8.3) | Severe hypoglycemia: 5/34 (14.7); DKA: 2/34 (5.9) |  |  |
| Microalbuminuria Collaborative, 199586 | 5/36 (13.9) | 3/34 (8.8) |  |  | \*NR  | \*NR |  |  |  |  |  |  |

IT = intensive treatment; CT = conventional treatment; DKA = diabetic ketoacidosis
\*Study reported 3/70 (4.3%) withdrawals due to serious adverse events overall (1 death, 1 leukemia, 1 acute renal failure), but did not report these outcomes by treatment group.